INST OX‐05‐024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial

Hepatocellular Carcinoma (HCC) incidence is increasing in the USA. Gemcitabine (G) and oxaliplatin (O) are active in HCC and biliary duct cancer (BDC). Erlotinib (E) is an EGFR tyrosine kinase inhibitor (TKI) with known activity against both. We sought to evaluate the efficacy of the combination G+O...

Descripción completa

Detalles Bibliográficos
Autores principales: Patt, Yehuda Z., Murad, Waheed, Fekrazad, Mohammed H., Baron, Ari D., Bansal, Pranshu, Boumber, Yanis, Steinberg, Kim, Lee, Sang‐Joon, Bedrick, Ed, Du, Ruofei, Lee, Fa Chyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603839/
https://www.ncbi.nlm.nih.gov/pubmed/28801995
http://dx.doi.org/10.1002/cam4.1138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603839/
https://www.ncbi.nlm.nih.gov/pubmed/28801995
http://dx.doi.org/10.1002/cam4.1138

Ejemplares similares